Symbols

PYXS

Pyxis Oncology·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

MACD Golden Cross

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PYXS

Pyxis Oncology, Inc.

A diversified oncology company focused on developing therapeutics to target difficult-to-treat cancers

Industry

Pharmaceutical

Established Date

06/11/2018

Listing Date

10/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pyxisoncology.com

Security Type

Common stock

Office address

321 Harrison Avenue Boston Massachusetts 02118

Business

Introduction

Pyxis Oncology, Inc., was incorporated in Delaware on June 11, 2018. The company is a clinical-stage oncology company advancing a development strategy focused on addressing the unmet medical needs of patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC).

Company Financials

EPS

PYXS has released its 2025 Q4 earnings. EPS was reported at -0.28, versus the expected -0.34, beating expectations. The chart below visualizes how PYXS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PYXS has released its 2025 Q4 earnings report, with revenue of 11.04M, reflecting a YoY change of NaN%, and net profit of -18.11M, showing a YoY change of 49.10%. The Sankey diagram below clearly presents PYXS's revenue sources and cost distribution.